Senores Pharmaceuticals Ltd has recently acquired 14 Abbreviated New Drug Applications (ANDAs) from Dr Reddy’s Laboratories through its wholly owned US subsidiary. The acquisition package includes 13 USFDA-approved applications and one pending approval, representing a market opportunity of approximately $421 million based on IQVIA data and $1.13 billion according to Symphony data. This move is aligned with the company’s objectives outlined in its Red Herring Prospectus, as Senores will be financing the acquisition using proceeds from its recent initial public offering.
Managing Director Swapnil Shah stated that the acquired portfolio consists of controlled substances and general category products that can be distributed through various channels, meeting the needs of government, retail, and specialty clinics. The acquired products cover various therapeutic areas and will broaden Senores’ offerings in the US market, with potential value in other globally regulated and semi-regulated markets.
Senores Pharmaceuticals currently operates two formulation manufacturing facilities – an FDA-approved plant in Atlanta and a WHO-GMP approved facility in Ahmedabad, India – along with two API manufacturing facilities near Ahmedabad. The company’s portfolio includes 27 ANDAs and 21 CMO/CDMO commercial products approved for US distribution. The shares of Senores Pharmaceuticals Ltd closed at ₹564.10 on Tuesday, a 6.33% increase on the NSE.
Overall, this acquisition will significantly enhance Senores Pharmaceuticals’ presence in the pharmaceutical market and align with its strategic growth plans.
